124 related articles for article (PubMed ID: 36889930)
1. Design, synthesis, anticancer evaluation,
El-Zahabi MA; Elkady H; Sakr H; Abdelraheem AS; Eissa SI; El-Adl K
J Biomol Struct Dyn; 2023; 41(24):15106-15123. PubMed ID: 36889930
[TBL] [Abstract][Full Text] [Related]
2. Novel promising benzoxazole/benzothiazole-derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis.
Elkady H; El-Adl K; Sakr H; Abdelraheem AS; Eissa SI; El-Zahabi MA
Arch Pharm (Weinheim); 2023 Sep; 356(9):e2300097. PubMed ID: 37379240
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
El-Zahabi MA; Sakr H; El-Adl K; Zayed M; Abdelraheem AS; Eissa SI; Elkady H; Eissa IH
Bioorg Chem; 2020 Nov; 104():104218. PubMed ID: 32932121
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, anticancer evaluation, and
Kotb AR; Abdallah AE; Elkady H; Eissa IH; Taghour MS; Bakhotmah DA; Abdelghany TM; El-Zahabi MA
RSC Adv; 2023 Apr; 13(16):10488-10502. PubMed ID: 37021105
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs.
Mabrouk RR; Abdallah AE; Mahdy HA; El-Kalyoubi SA; Kamal OJ; Abdelghany TM; Zayed MF; Alshaeri HK; Alasmari MM; El-Zahabi MA
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569792
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. Mechanochemical Synthesis and Molecular Docking Studies of New Azines Bearing Indole as Anticancer Agents.
Ibrahim MS; Farag B; Al-Humaidi JY; Zaki MEA; Fathalla M; Gomha SM
Molecules; 2023 May; 28(9):. PubMed ID: 37175279
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.
Kotb AR; Bakhotmah DA; Abdallah AE; Elkady H; Taghour MS; Eissa IH; El-Zahabi MA
RSC Adv; 2022 Nov; 12(52):33525-33539. PubMed ID: 36505721
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
14. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
16. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
17. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
Naaz F; Preeti Pallavi MC; Shafi S; Mulakayala N; Shahar Yar M; Sampath Kumar HM
Bioorg Chem; 2018 Dec; 81():1-20. PubMed ID: 30081353
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
